179 In the index

TB-500 TB-500

A lab-made peptide marketed for wound healing, flexibility, and injury recovery in research-chemical circles. Almost all the supporting evidence comes from animal wound-healing studies; there are no real controlled human trials of it.

Also known as Thymosin beta-4 fragment, Thymosin Beta 4, THYMOSIN BETA 4 ACETATE, Thymosin beta4 Acetate, Thymosin beta 4?, Thymosin b4 (cattle), orb1910607

Effects Heal

Routes Subcutaneous

Legal status Research chemical

WADA Banned at all times

Molecular Structure of C₂₁₂H₃₅₀N₅₆O₇₈S

Drag to rotate · scroll to zoom

Chemistry

Formula: C212H350N56O78S
Molar mass: 4963
PubChem CID: 45382195
IUPAC name: 4-[[2-[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[1-[2-[[1-[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[2-[[2-[[2-[[1-[2-[[2-[(2-acetamido-3-hydroxypropanoyl)amino]-3-carboxypropanoyl]amino]-6-aminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-carboxypropanoyl]amino]-4-methylsulfanylbutanoyl]amino]propanoylamino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-6-aminohexanoyl]amino]-3-phenylpropanoyl]amino]-3-carboxypropanoyl]amino]-6-aminohexanoyl]amino]-3-hydroxypropanoyl]amino]-6-aminohexanoyl]amino]-4-methylpentanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-3-hydroxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxybutanoyl]amino]-5-amino-5-oxopentanoyl]amino]-4-carboxybutanoyl]amino]-6-aminohexanoyl]amino]-4-amino-4-oxobutanoyl]pyrrolidine-2-carbonyl]amino]-4-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-6-aminohexanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxybutanoyl]amino]-3-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-5-amino-5-oxopentanoyl]amino]-4-carboxybutanoyl]amino]-6-aminohexanoyl]amino]-5-amino-5-oxopentanoyl]amino]propanoylamino]acetyl]amino]-5-[(1-carboxy-2-hydroxyethyl)amino]-5-oxopentanoic acid
InChIKey: UGPMCIBIHRSCBV-UHFFFAOYSA-N

Reported dosing

User-reported

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose 2-2.5 mg, 1-2 times weekly

Reported range 2-5 mg weekly, sometimes with a higher 'loading' phase

Route Subcutaneous injection

Frequency 1-2 times weekly

Duration 4-6 week course (unregulated use), sometimes followed by lower-dose maintenance

A synthetic fragment of thymosin beta-4 marketed for wound healing and injury recovery; almost all supporting evidence comes from animal studies, with no controlled human trials. Not FDA-approved.

Where this comes from Animal studies only; user-reported/research-chemical vendor literature

There is no approved human dosing for this compound. The figures above are what users and vendors report, not what has been established as safe or effective. Treat them as a record of what is done, not as guidance.